Feasibility Study Using Zone-MPC Controller, HMS and Technosphere® Insulin Inhalation System From MannnKind Corp

• Status: Completed
• Trial end date: 2013-06-01

Summary

This clinical trial is a feasibility study to assess the performance of an Artificial Pancreas (AP) device using the Artificial Pancreas System (APS©) platform for subjects with type 1 diabetes using rapid-acting insulin as well as preprandial inhaled insulin (Technosphere® Insulin Inhalation System by MannKind Corporation). The goal of this proposed study is to explore the feasibility of using multiple insulin delivery routes in order to mimic the physiology of both first- and second-phase insulin secretion. The intent is to exploit the rapid action achieved by inhaled insulin to compensate for part of the meals and utilize the conventional subcutaneous route for management of basal insulin and as second-phase meal-related insulin.

• Phase: N/A

Details

• Lead Sponsor: Sansum Diabetes Research Institute; William Sansum Diabetes Center
• Collaborator: Juvenile Diabetes Research Foundation
• Treatments: Insulin; Insulin, Globin Zinc; Pancreatin; Pancrelipase